HEPATITIS C
Hepatitis C is parenterally transmitted causing a
mild acute hepatitis. 50% of patients develop chronic infection and hepatitis,
20% of whom develop cirrhosis. These patients are at risk of hepatocellular
carcinoma. The other 50% recover completely. In Britain 0.1 to 0.5% of the
population are infected with this virus. The rate of progression of the disease
is variable. In 20% of cases cirrhosis develops in 5-10 years. But in the
majority the prognosis is good. Hepatitis C virus is an RNA virus, which has
around 12 or more genotypes according to the amino acid sequence. The route of
transmission is parenteral in 40% and includes hemophiliacs,
thalassemics, drug abusers and patients on hemodialysis. Sexual transmission,
perinatal spread and intra-familial spread accounts for around 60%. The
prevalence in the general population in Western countries is 0.5-3%. Prevalence
among blood donors was found here to be 3.61%. The highest in Egyptians (27.2%)
and around 1.7% in Saudis. Other than rise in liver enzymes like SGOT and SGPT,
the bilirubin may be mildly raised. 2nd generation ELISA is quite
specific and sensitive. However the best is PCR which detects HCV as early as 2
weeks after exposure.
For more on HEPATITIS click here
Treatment: other than symptomatic treatment and improvement in the nutritional status of the patient,
specific measures undertaken include Interferon a
and use of anti-viral drug Ribavarin. Interferon a
(Intron A) treatment is indicated for patients with well documented chronic
hepatitis C in whom other causes of chronic hepatitis have been excluded and who
have at least 2-fold elevation of serum ALT (SGPT). Interferon a
is used in a dosage of 3-5 million units thrice weekly subcutaneously for a
period of 6-12 months. This normalizes transaminases in 50-85% of cases, but
relapse is common (60%). Around 20% have a sustained remission. The early side
effects are influenza-like illness. Later side effects include malaise, muscle
aches, poor appetite, weight loss, leucopenia, and thrombocytopenia. Unusual
side effects are psychosis, seizures, proteinuria, skin rashes and
cardiomyopathy. Ribavarin is a nucleoside analogue that is taken orally. The
drug may be a better choice for patients with cirrhosis, who respond poorly to
Interferon. The chief side effect is hemolysis.
Click here for the latest trials on the
treatment of Hepatitis C!